Please select the eligibility criteria that correspond to the clinical trial below.
Title: Home-fortification Approaches for the Prevention of Malnutrition in Pregnant and Lactating Women and Their Children in Bangladesh: Program Effectiveness Study
Brief Summary: The program effectiveness study aims to assess the effect of a lipid-based nutrition supplement (LNS) and micronutrient powder (MNP) provided in a programmatic context for improving maternal nutritional status during pregnancy and lactation (LNS only), and preventing malnutrition in infants and young children (LNS and MNP) in Bangladesh.


Options:
A: Inclusion Criteria:

* HIV infected
* CD4 count \> 200 cells/μL
* ALT \< 2.5 x upper limit of normal (ULN)
* Hemoglobin (Hb) \> 7 g/dL
* Age \> 18 years, or \<18 years and married (considered emancipated minors in Malawi)
* Ability to give informed consent
* Evidence of HIV infection, as documented by 2 positive Enzyme-Linked Immunosorbent Assays (ELISA's); or 1 positive ELISA, and 1 Western blot (WB); or 2 separate concurrent rapid tests. These are the World Health Organization (WHO) acceptable criteria for diagnosing HIV-1 infection in adults.
* Currently pregnant (with a single or multiple fetuses)
* Gestation \< 34 weeks
* No serious current complications of pregnancy
* Intention to breastfeed
* Intention to deliver at the institution in which the study is based
* Other than HIV, no active serious infection, such as tuberculosis or other potentially serious illnesses
* No previous use of antiretrovirals including the HIVNET 012 regimen
B: Inclusion Criteria:

* At least 18 years of age
* No more than 20 wk of gestation
* Given Ante-natal Cards of the Ghana Health Service
* Completed the initial routine ante-natal examination at the clinics
* HIV negative or status unknown (as from the Ante-natal card)
* Free from chronic disease e.g. malignancy requiring frequent medical attention (as from the Ante-natal card)
* Residing in the Manya Krobo or Yilo Krobo district
* Prepared to sign an informed consent
* Living in the area throughout the duration of the study
* Acceptance of home visitors

Exclusion Criteria:

* Known asthmatic or history of allergy towards peanut or milk products
* Concurrent participation in another clinical trial
* Severe illness warranting hospital referral
C: Inclusion Criteria:

* Ultrasound confirmed pregnancy of no more than 20 completed gestation weeks
* Permanent resident of Mangochi District Hospital, Malindi Hospital or Lungwena Health Centre catchment areas
* Availability during the period of the study
* Signed informed consent

Exclusion Criteria:

* Less than 15 years of age
* Need for frequent medical attention due to a chronic health condition
* Diagnosed asthma treated with regular medication
* Severe illness warranting hospital referral
* History of allergy towards peanuts
* History of anaphylaxis or serious allergic reaction to any substance, requiring emergency medical care
* Pregnancy complications evident at enrolment visit (moderate to severe oedema, blood Hb concentration \< 5 g / dl, systolic blood pressure (BP) \> 160 mmHg or diastolic BP \> 100 mmHg)
* Earlier participation in the iLiNS-DYAD-M trial
* Concurrent participation in any other clinical trial
D: Inclusion Criteria:

* Gestational age ≤ 20 weeks
* Planning to remain in the study area during pregnancy and the following three years (i.e., a permanent resident of the study area)

Exclusion Criteria:

* Pregnancy identified and registered in the CHDP program before the beginning of the enrollment.

Answer: D